期刊
PHARMACOLOGICAL RESEARCH
卷 60, 期 2, 页码 99-106出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2009.04.003
关键词
Cannabinoids; Cardiovascular disease; Cardiac function; Heart failure; Cardiomyopathy; Cirrhosis; Doxorubicin
资金
- Division of Intramural Clinical and Biological Research, NIAAA
- NIH
Endocannabinoids are part of a bioactive lipid signaling system, not only in the central nervous system but also in various peripheral organs. Accumulating evidence implicates dysregulation of the endocannabinoid system (ECS) in the pathogenesis of various cardiovascular diseases, including hypertension, atherosclerosis, myocardial infarction, hemorrhagic or septic shock, heart failure and cardiovascular complications of liver cirrhosis. Even though the benefit of chronic cannabinoid 1 (CB1) receptor blockade with the currently available compounds may not outweigh the risks in chronic conditions such as obesity, modulation of the ECS may hold great therapeutic promise in various cardiovascular conditions/disorders. In this review we will discuss recent advances in understanding the role of CB, receptors and endocannabinoids in the regulation of cardiac function in cirrhotic carchomyopathy and in doxorubicin-induced heart failure. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据